Find → Understand → Decide
APR-246
Discovery priority: LOW · UNKNOWN
Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.
Why investigate?
Why stranded (event context): inadequate public evidence
Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established
Company/trial failed before biology? UNKNOWN
Biology implicated: UNCLEAR · Failure context: UNKNOWN
MODEL INFERENCE · UNKNOWN confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.
Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN
Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.
Existing buyer gates
Human Signal: UNKNOWN
Cheap Truth: UNKNOWN
Clean Rights: UNKNOWN
Market Pull: UNKNOWN
No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.
Evidence timeline
No supported strandedness event. Completion alone does not prove abandonment.
Freshness is claim-specific
Fetching an old filing today does not establish current ownership or program status.
clinicaltrials · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
Registry observations (1)
NCT03588078 · COMPLETED · PHASE1, PHASE2 · Myelodysplastic Syndrome With Gene Mutation; Acute Myeloid Leukemia With Gene Mutations; Myeloproliferative Neoplasm; Chronic Myelomonocytic Leukemia · Trial sponsor Groupe Francophone des Myelodysplasies
Reported aliases: PRIMA-1MET; Methylated analogue to PRIMA-1. Identity, treatment role and exposure require review.